Testosterone pp 513-528 | Cite as

Testosterone in male contraception

  • Eberhard Nieschlag
  • Hermann M. Behre

Abstract

The first of a series of topics that Kate Noble lists in an article in a special TIME-Magazine issue (Winter 1997/1998) on “Shape of things to come” in the years 1999 to 2500 is: “Male birth control pill or contraceptive injection becomes commonly available”. This prediction does not come as a surprise to the researcher active in the field. The surprising element is the year designated to witness the “common availability”: 1999! From all we know today, this male contraceptive will be hormone-based and while scientists have believed for a long time that the principle of hormonal male contraception is ready to be converted into a viable consumable drug, the pharmaceutical industry, for whom drug development is an inherent task, has refused to fulfill this task for hormonal male contraception. Confronted with this reluctance, leading scientists active in the field of male contraception felt compelled to draft the “Weimar Manifesto on Male Contraception” in June 1997 (see insert on opposite page) and to urge industry to assume an active role in male contraceptive development. Since then, at least three companies have publicly declared their new commitment to male contraception development. An enthusiastic article in the Guardian on October 6, 1997 (“Trials may put men on the pill by 2000”) predicts general availability of a hormonal male contraceptive by 2000. This statement probably gave rise to TIME’s optimism.

Keywords

Androgen Endometriosis Acne Indonesia Bonnet 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson RA, Baird DT (1997) Progress towards a male pill. IPPF Med Bull 31: 3–4Google Scholar
  2. Aribarg A, Sukcharoen N, Chanprasit Y, Ngeamvijawat J, Kriangsinyos R (1996) Suppression of spermatogenesis by testosterone enanthate in Thai men. J Med Assoc Thai 79: 624–629PubMedGoogle Scholar
  3. Arysad KM (1993) Sperm function in Indonesian men treated with testosterone enanthate. Int J Androl 16: 355–361CrossRefGoogle Scholar
  4. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocr Metab 81: 757–762PubMedCrossRefGoogle Scholar
  5. Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocr Metab 74: 84–90PubMedCrossRefGoogle Scholar
  6. Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994) Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist Cetrorelix over 8 days in normal men. Clin Endocr 40: 241–248PubMedCrossRefGoogle Scholar
  7. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995 a) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocri Metab 80: 2394–2403Google Scholar
  8. Behre HM, Kliesch S, Lemcke B, Nieschlag E (1995 b) Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone in normal men. 77th Annual Meeting of the Endocrine Society. Washington, DC, USA, OR29–6Google Scholar
  9. Bhasin S, Berman N, Swerdloff RS (1994) Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone ( GnRH) agonist and testosterone treatment. J Androl 15: 386–391Google Scholar
  10. Bremner WJ, Bagatell CJ, Steiner RA (1991) Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive. J Clin Endocr Metab 73: 465–469PubMedCrossRefGoogle Scholar
  11. Cao J, Yuan J, Jin W (1996) Clinical trial of an anti-fertility method with testosterone enanthate in normal men. Chung Hua I Hsueh Tsa Chih 76: 335–337PubMedGoogle Scholar
  12. Chen ZD, Cai SL, Chan YZ, Jian R, Zhao QW, Gu WZ, Fang RY, Zhang YP (1986) Clinical study of testosterone undecanoate compound on male contraception. J Clin Androl 1: 18–20Google Scholar
  13. Delanoe D, Fougevrollas B, Meyer L, Thonneau P (1984) Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1: 276PubMedCrossRefGoogle Scholar
  14. Fogh M, Corker CS, Hunter WM, McLean H, Philip J, Schon G, Skakkebaek NE (1979) The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men. Acta Endocrinol 91: 545PubMedGoogle Scholar
  15. Fogh M, Corker CS, McLean H (1980) Clinical trial with levornorgestrel and testosterone oenanthate for male fertility control. Acta Endocrinol 95: 251–257PubMedGoogle Scholar
  16. Guerin JF, Roullet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11: 187–199PubMedCrossRefGoogle Scholar
  17. Hamilton DW, Waites GMH (1989) (eds) Scientific basis of fertility regulation: Cellular and molecular events in spermatogenesis. Cambridge University Press, Cambridge, pp 315– 321Google Scholar
  18. Handelsman DJ, Conway AJ, Boylan LM (1992) Suppression of human spermatogenesis by testosterone implants. J Clin Endocr Metab 75: 1326–1332PubMedCrossRefGoogle Scholar
  19. Knuth UA, Behre HM, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestos- terone-hexoxyphenylpropionate ( Anadur) for male fertility regulation. Fertil Steril 44: 814–821Google Scholar
  20. Knuth UA, Yeung CH, Nieschlag E (1989) Combination of 19-nortestosterone-hexyoxyphe- nylpropionate (Anadur) and depot-medroxyprogesterone-acetate ( Clinovir) for male contraception. Fertil Steril 51: 1011–1018Google Scholar
  21. Leonard JM, Paulsen CA (1978) Contraceptive development studies for males: oral and parenteral steroid hormone administration. In: Pantanelli DJ (ed) Hormonal control of male fertility. Department of Health, Education and Welfare, National Institutes of Health, Bethesda, p 223Google Scholar
  22. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvala L, Motta R, Pavani A, Capelli M, Flamigni C (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocr Metab 81: 3018–3023PubMedCrossRefGoogle Scholar
  23. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C (1997) An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 68: 844–850PubMedCrossRefGoogle Scholar
  24. Moltz L, Rommler A, Post K, Schwartz U, Hammerstein J (1980) Medium dose cyproterone acetate (CPA): effects on hormone secrection and on spermatogenesis in man. Contraception 21: 393PubMedCrossRefGoogle Scholar
  25. Moudgal NR, Ravindrath N, Murthy GS, Dighe RR, Aravindan GR, Martin F (1992) Long- term contraceptive efficacy of vaccine of ovine follicle-stimulating hormone in male bonnet monkeys ( Macaca radiata ). J Reprod Fertil 96: 91–102Google Scholar
  26. Moudgal NR, Sairam MR, Krishnamurthy HN ( 1997 a) Immunization of male bonnet monkeys ( Macaca radiata) with a recombinant FSH receptor preparation affects testicular function and fertility. Endocrinology 138: 3065–3068.Google Scholar
  27. Moudgal NR, Jeyakumar M, Kishnamurthy HN, Sridhar S, Krishnamurthy H, Martin F (1997 b) Development of male contraceptive vaccine - a perspective. Hum Reprod Update 3: 335–346Google Scholar
  28. Moudgal NR, Murthy GS, Prasanna Kumur KM, Martin F, Suresh R, Medhamurthy R, Patil S, Sehgal S, Saxena B (1997c) Responsiveness of human male volunteers to immunization with ovine follicle stimulating hormone vaccine: results of a pilot study. Hum Reprod 12: 457–463PubMedCrossRefGoogle Scholar
  29. Nieschlag E (1986) Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra J (eds) Male contraception: Advances and Future Prosptects. Harper & Row, Philadelphia pp 395–400Google Scholar
  30. Nieschlag E, Behre HM (1996) Hormonal male contraception: Suppression of spermatogenesis with GnRH antagonists and testosterone. In: Filicori M, Flamigni C (eds) Treatment with GnRH analogs: Controversies and perspectives. Parthenon, London, 243–248Google Scholar
  31. Nieschlag E, Hoogen H, Bolk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18: 607–614PubMedCrossRefGoogle Scholar
  32. Nieschlag E, Behre HM, Weinbauer GF (1992) Hormonal male contraception: A real chance? In: Nieschlag E, Habenicht UF (eds) Spermatogenesis - fertilization - contraception. Molecular, cellular and endocrine events in male reproduction. Springer, Heidelberg, pp 477–501Google Scholar
  33. Pavlou SN, Wakefield G, Schlechter NL, Lindner J, Souza KH, Kamilaris TC, Konidaris S, Rivier JE, Vale WW, Toglia M (1989) Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J Clin Endocrinol Metab 73: 1360–1369CrossRefGoogle Scholar
  34. Pavlou SN, Herodotou D, Curtain M, Minaretzis D (1994) Complete suppression of spermatogenesis by co-administration of a GnRH antagonist plus a physiologic dose of testosterone. Proceedings of the 76th meeting of the Endocrine Society, Anaheim, CA, 1324Google Scholar
  35. Schearer SB, Alvarez-Sanches F, Anselmo G, Brenner P, Coutinho E, Lathen-Faundes A, Frick J, Heinild B, Johansson EDB (1978) Hormonal contraception for men. Int J Androl Suppl 2: 680–712CrossRefGoogle Scholar
  36. Schurmeyer T, Knuth UA, Freischem CW, Sandow J, Akhtar FB, Nieschlag E (1984) Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. J Clin Endocr Metab 59: 1–6CrossRefGoogle Scholar
  37. Soufir JC, Jouannet P, Marson J, Soumah A (1983) Reversible inhibition of sperm production and gonadotropin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol 102: 625–632PubMedGoogle Scholar
  38. Srinath BR, Wickings EJ, Witting CH, Nieschlag E (1983) Active immunization with follicle stimulating hormone for fertility control: a 4 1/2-year study in male rhesus monkeys. Fertil. Steril. 40: 110–117Google Scholar
  39. Wang C, Yeung KK (1980) Use of a low dosage oral cyproterone acetate as a male contraceptive. Contraception 21:245 Weinbauer GF, Nieschlag E (1996) The Leydig cell as a target for male contraception. In: Payne AH, Hardy MP, Russell LD (eds), The Leydig Cell. Cache River Press, Vienna, pp 629–662Google Scholar
  40. Weinbauer GF, Surmann FJ, Nieschlag E (1987) Suppression of spermatogenesis in a non-human primate (Macaca fascicularis) by concomitant gonadotropin-releasing hormone ( GnRH) antagonist and testosterone treatment. Acta Endocrinol 114: 138–146Google Scholar
  41. Weinbauer GF, Göckeler E, Nieschlag E (1988) Testosterone prevents complete suppression of spermatogenesis in the gonadotropin-releasing hormone (GnRH) antagonist-treated non-human primate ( Macaca fascicularis ). J Clin Endocr Metab 67: 284–290Google Scholar
  42. Weinbauer GF, Khurshid S, Fingscheidt U, Nieschlag E (1989) Sustained inhibition of sperm production and inhibin secretion induced by a gonadotropin-releasing hormone antagonist and delayed testosterone substitution in non-human primates ( Macaca fascicularis ). J Endocr 123: 303–310Google Scholar
  43. Weinbauer GF, Limberger A, Behre HM, Nieschlag E (1992) The GnRH antagonist cetrorelix inhibits spermatogenesis in the non-human primate: effects of delayed high dose testosterone substitution. Proceedings of the 9th International Congress of Endocrinology, Nice, France, 419Google Scholar
  44. WHO ( 1972 –1995) Special Programme of Research, Development and Research Training in Human Reproduction. Annual and Biannual Reports, WHO, GenevaGoogle Scholar
  45. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 955–959CrossRefGoogle Scholar
  46. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60: 1062–1068Google Scholar
  47. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65: 821–829Google Scholar
  48. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1995) Rates of testosterone-induced suppression to severe oligozoospermia or,azoospermia in two multinational clinical studies. Int J Androl 18: 157–165CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Eberhard Nieschlag
  • Hermann M. Behre

There are no affiliations available

Personalised recommendations